Life Sciences Archive » October, 2008

Life Sciences - October, 2008

162 articles

• Leaps and Bounds: Notable Firm News
• NJ Judge Refuses To Block Datascope Merger
• Faux-Blood Maker Says Med. Journal Article Libelous
• Court Affirms Noninfringement Of J&J Suture Patent
• Why The Third Restatement Still Falls Short
• Trends In Subprime-Related Securities Fraud Actions
• Schering-Plough To Pay $31M In Mo. AWP Suit
• Plaintiffs Lawyer, Edwards Fundraiser Fred Baron Dies
• Group Petitions FDA To Ban Avandia
• 3rd Circ. Affirms Fen-Phen Claim Denial
• Business Method Patents Down But Not Out: Experts
• Paxil Judge Closes Door But Opens Window For GSK
• Injunctions Harder To Win In Post-EBay Courts
• Bifurcation Warranted In Lotrel Patent Spat: Judge
• Mandatory Compliance With 'Voluntary' Codes
• VNUS Ends Patent Fight Over Vein Laser Treatments
• Biogen Says Another Falls Ill After Taking MS Drug
• House Slams FDA In Run-Up To High Court Drug Case
• Slower Growth Forecast For US Drug Market In 2009
• Case Over Weight Loss Drug Gets A Little Thinner
• FDA's Assessment Of Bisphenol A 'Inadequate': Panel
• Elan Faces Shareholder Suit Over Alzheimer's Drug
• AstraZeneca Sues Handa Again Over Seroquel XR
• Zyprexa MDL Judge Orders Conn. To Produce Records
• FDA Warns Bayer Over Aspirin-Supplement Combos
• Zydus Says Teva Patents Violate Antitrust Laws
• Cipro: A Road Map For Reverse Payment Litigation
• Medicis Hit With Securities Fraud Class Action
• Employment Practice: Mayer Brown
• Shareholders Sue ImClone, Lilly Over Pending Merger
• State Failure-To-Warn Claims Found Preempted
• On-The-Job Harmonization Of European Patent Law
• NMT Jolts WL Gore Over Patented Heart Implant
• Novartis Adds Wyeth To Hemophilia Patent Hit List
• 2 Fen-Phen Plaintiffs' Attorneys Disbarred In Ky.
• Backdating Suit Against Affymetrix Execs Continues
• Citrucel Supplier Can Sue Chemical Maker: Court
• Genentech's Rituxan, Others, Under Fire From Sanofi
• Nigeria Case Settlement In Sight For Pfizer
• Teva Wins $100M Settlement From Broker Over ARS
• Thoratec Issues Correction Of HeartMate II Pump
• Watson Says Barr Infringes Patent For Oxytrol
• St. Jude Wields Patents Against Device Maker
• Squeaky Hip Implant Suit Against Stryker Tossed
• Bristol-Myers Shells Out $21M To Settle Orencia Suit
• EU Rejects Cymbalta For Fibromyalgia Treatment
• Kan. Sues Slew Of Drugmakers Over AWPs
• Plaintiff Says Clock Didn't Run Out On Ephedra Claim
• Roche Sues Orchid Over Newest Boniva Patent
• Aerocrine Sues Apieron Over Asthma Monitor
• Loyalty Discounts Not Necessarily Win-Win
• Bayer Prevails Again In Baycol MDL
• The Federal Preemption Battle Has Just Begun
• Judge Rules Against Recipients In Tissue-Theft MDL
• Sanofi Pulls Obesity Drug Acomplia From EU Market
• Otsuka Sues Apotex Again Over Generic Abilify
• Endo Sues Barr Over Opana Patents
• FDA Data On Foreign Drugmakers Flawed: GAO
• Report Questions Pfizer's Anti-Smoking Drug
• Judge Orders Settlement Talks In Zyprexa MDL
• Takeda, Mylan Drop Claims In Diabetes Drug Suit
• Judge Hands Medtronic Win On Rapid-Exchange Bar
• Jury Taps Wyeth For $3M In Fen-Phen Suit
• Fed. Circ. Upholds Preliminary Injunction On Biaxin XL
• Steris Hasn't Solved Manufacturing Violations: FDA
• 1 In 4 Biotech Drugs Gets Safety Warning: Study
• Cordis Hits Boston Scientific Over New Taxus Stent
• $18.3M Fee Fund Gets Green Light In Medtronic MDL
• Lilly Takes $1.4B Charge In Settlement Anticipation
• 3rd Circ. Blocks Bid For Rehearing In Vioxx Suit
• Shareholders Launch Fraud Suit Against ArthroCare
• Plaintiffs Lack Standing In Flonase Suit: GSK
• Feds Want Device Maker's Subpoena Suit Tossed
• Liver Failure Suit Tackles Settlement Enforceability
• Pfizer To Settle Celebrex, Bextra Suits For $894M
• Sens. Scrutinize Medical Industry Funding For Doctors
• Surgery Tool Maker Sues Rival Over Drill Guide Patent
• FDA Adds Boxed Warning To Psoriasis Drug
• Scientists Grade Agencies On Media Policies
• Effects Of CMS Final Rules On Medicare, MIPPA
• Leiner Health Gets Confirmation For Ch. 11 Exit
• Lawyers Seek To Multiply Digitek Suits Against Actavis
• Qui Tam Suit Over OxyContin A No-Go: Judge
• Merck Pushes To Sever Plaintiffs In Fosamax MDL
• Patient Care Ombudsman And Health Care Bankruptcy
• USPTO Says Blocked Rules Lie Within Its Authority
• Okla. Sues McKesson Over Reported Drug Prices
• German Court Clears CoreValve In Patent Spat
• Fed. Circ. Affirms Dismissal Of Reverse Payment Suit
• Protective Order For Apotex Employees Mostly Denied
• FDA Warns Boehringer About Misleading Mirapex Ads
• Judge Drops 37 More Plaintiffs From Baycol MDL
• UK Court Denies Overcharge Damages In Cartel Suits
• Get Ready For Antitrust Trial, Judge Tells Sanofi
• Chair Of BPA Safety Panel Probed Over $5M Gift
• Hi-Tech Loses Motion And Now Awaits FDA Decision
• FDA Warns CR Bard Over 'Adulterated' Med. Devices
• Lawmakers Probe Bayer Drug-Supplement Marketing
• Biolase, Diodem Settle Dispute Over Patent Deal
• State AGs Ask Baby Product Cos. To Cut Bisphenol A
• AstraZeneca Sues Ivax, Teva Over Nexium Patent
• Appeal Over Nellson's Mgmt. Incentive Plan To Go On
• DLA Piper Snags Patent Maven From Townsend
• FDA OKs Boston Scientific's New Taxus Stent
• Alcon Sues Synergetics Over Eye Laser Patent
• Wyeth Wins Philly Fen-Phen Case
• Fed. Circ. Upholds Preliminary Ban on Roche's Mircera
• J&J Racks Up $69M In Ortho Evra Settlements: Report
• USPTO Rule Change Could Raise Costs For Appellants
• Schulte Roth Seeks $1.5M In Fees For Quigley Ch. 11
• Patent Re-Exams Are Growing As Key Defense Tactic
• Biovail In Trouble With Shareholders Over Aplenzin
• Patent In $41M Contact Lens Suit Invalid: Re-Exam
• Prednisone Suit Proceeds Against Watson, Qualitest
• Ovarian Cancer Screening Test Not Approved: FDA
• Candela Skin Treatment Patent Case Sags
• State Suit Not Preempted By Federal Vaccine Law: Ga.
• Generic-Drug Companies And Federal Preemption
• Managing The EU-US Discovery Conflict
• SEPTA Settles Hazardous Waste Violations For $1M
• Walgreen Seeks To Toss Wal-Vert Trademark Ruling
• Pfizer's Bextra Marketing 'Deceptive': Blue Cross
• Top Companies Singled Out For Emissions Reductions
• Courts Can Defer To FDA On Diet Products: 11th Circ.
• Lawmakers Question FDA's Handling Of Actavis Recall
• Court Thins Misconduct Claims In Syringe Patent War
• Suit Says Crestor Infringes Teva Patent
• DOJ Drops Motion Against Ranbaxy
• Pfizer Accused Of Manipulating Epilepsy Drug Data
• Bayer's Yaz Ads 'Misleading:' FDA
• 2 Wal-Mart Pharmacists May Be Eligible For Overtime
• AtheroGenics Converts Ch. 7 Bankruptcy Into Ch. 11
• High Court May Not Hear Any IP Cases This Term
• Lilly Settles Zyprexa State Claims In $62M Deal
• Drugmakers Promise Label Changes For Cold Meds
• Aventis Wants Sens.' Letter Excluded In Arava Case
• Judge Bends But Doesn't Break Knee Case
• Fed. Circ. Upholds Ruling For Aventis Over ALS Drug
• Justice Breyer Unloads Stocks To Avoid Recusals
• Supreme Court Won't Hear Appeal In Stent Dispute
• Judge Allows Ariad To Appeal Enbrel Case
• Eli Lilly Picks Up ImClone For $6.5B
• High Court Scolds FTC In Tobacco Preemption Case
• Heller Employees Won't Get Vacation Pay: Report
• Cardinal Health To Pay $34M To Settle Painkiller Case
• Judge To Permanently Enjoin Roche's Mircera
• Analysis Of Walgreen-Longs Merger Misses Mark: CVS
• Cooley Godward Snags Displaced Heller Lawyers
• Representatives Slap FDA Over PR Contract Tactics
• GSK Loses Bid To Toss Claims Over Paxil Suicide
• Low Patent Allowance Hurts Innovation: Experts
• Doctors Urge FDA To Yank Children's Cold Meds
• Court Bars Presuit Damages In Bone-Cleaning Case
• Congress Questions Medtronic On Kickbacks
• FDA's Challenge To Implied Outcomes Of ADHD Drugs
• FDA's View On Generic Drug Label Carve-Outs
• Medtronic, McDermott Ordered To Pay $4.4M In Fees
• Court OKs $40M Paxil Deal With Third-Party Payors
• Fla. AG Sues Merck To Recover Vioxx Payments
• Last US Suit Against AWB Over Oil-For-Food Tossed
• J&J Unit Scores $1.2B Judgment In Stent Feud
• US, EU Set Off On 'Patent Prosecution Highway'